This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Oct 31;122(18):3092-3.

doi: 10.1182/blood-2013-09-526657.

Can CRd be a standard for refractory myeloma?

Jesus San-Miguel¹

Affiliations

PMID: 24178959
DOI: 10.1182/blood-2013-09-526657

Free article

Comment

Can CRd be a standard for refractory myeloma?

Jesus San-Miguel. Blood. 2013.

Free article

. 2013 Oct 31;122(18):3092-3.

doi: 10.1182/blood-2013-09-526657.

Author

Jesus San-Miguel¹

Affiliation

¹ CLÍNICA UNIVERSIDAD DE NAVARRA.

PMID: 24178959
DOI: 10.1182/blood-2013-09-526657

No abstract available

PubMed Disclaimer

Comment on

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Wang M, et al. Blood. 2013 Oct 31;122(18):3122-8. doi: 10.1182/blood-2013-07-511170. Epub 2013 Sep 6. Blood. 2013. PMID: 24014245 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information